Clinical Trials
13 trialsNCT03581292 2026-05-27
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT07326566 2026-05-27
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT03180502 2026-05-26
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT03688178 2026-05-22
DERIVe
Duke University
Phase 2 Active not recruiting
NCT06413706 2026-05-22
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04984733 2026-05-18
ELEVATE
University of Southampton
Phase 2 Completed
NCT04394858 2026-05-13
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02308527 2026-05-12
BEACON
University of Birmingham
Phase 2 Completed
NCT07310784 2026-05-12
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
NCT05096481 2026-05-11
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05629702 2026-05-05
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT06649851 2026-05-05
G-CSF After Chemo-radiation in Patients With Glioblastoma
Massachusetts General Hospital
Phase 2 Recruiting